Professor Ignace Vergote speaks about his research into NKTR-102, a new drug for treating women with platinum-resistant/refractory ovarian cancer. In addition to the encouraging results of this trial, the study has found that that NKTR-102 only has limited side effects. Prof Vergote’s team will now look to do a large scale randomised trial to establish if this is effective in combination with traditional treatments such as carboplatin in order to treat all ovarian cancer patients.